Newsletter · 2026-07-31 · Ashutosh Agarwal

Argenx Makes Its First Acquisition and Mid Cap Biotechs Join the Buyers Club - The Biotech Patent Cliff & M&A - Week of July 31, 2026

A synthesis of what biotech podcasts said about the patent cliff, dealmaking and biotech financing for the week of July 31, 2026, including Argenx's first-ever acquisition, the widening roster of mid-cap biotech buyers, and the first very-early-stage biotech IPO since the COVID era.

The Biotech Patent Cliff & M&A

Week of July 31, 2026: Argenx Makes Its First Acquisition and Mid Cap Biotechs Join the Buyers Club

For two years the patent-cliff story has had a simple cast: a handful of giant drugmakers, staring down the day their biggest sellers lose patent protection, spending to plug the hole. This week the interesting move came from a company that isn't a giant and doesn't have a cliff. Argenx, a European biotech most people outside the sector have never heard of, made the first acquisition in its history. That sounds small. It isn't. It's the clearest sign yet that the club of companies with the cash and the confidence to go shopping is getting bigger, and that changes the math for everyone selling.

TL;DR

• A new tier of buyers has arrived. Argenx, worth north of $50 billion and trading near an all-time high, bought a small immunology developer, Forte, for about $2.2 billion, its first-ever deal. It joins a growing list of "not-quite-big-pharma" biotechs now writing billion-dollar checks (Vertex just did a $10 billion deal; GenMab paid $8 billion for Merus). More buyers means more competition for every target, and more leverage for sellers.
• An ex-Merck executive confirms the cliff is driving deals, but warns the money is going to a narrow band of companies. Kaida BioPharma CEO Stella Vnook says the patent cliff has created real M&A momentum, "and that's true." The catch: nearly all of it is aimed at drugs that have already cleared early trials, leaving genuinely early-stage companies starved for cash.
• The financing window that reopened is now showing up in actual deals. A panel of biotech insiders flagged the first very-early-stage IPO "since the COVID era" and the sixth reverse-merger-plus-big-financing of the year (versus about three all of last year), hard evidence that small biotechs finally have a second way out besides a takeover.

What's new

Argenx makes its first-ever acquisition, and that's the story. On BioCentury This Week, "Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard" (July 28), the editors, trade-press analysts, so read this as informed observation rather than a stock call, walked through Argenx buying a company called Forte for about $2.2 billion. Forte is developing an antibody against a target called CD122 for immune conditions, with "early data, but promising data in vitiligo and celiac disease," plus a program in alopecia. One drug, several diseases, what the industry calls a "pipeline in a product."

The reason this matters is what Argenx already is. It "built its business these past several years around Vivgart," a drug for a muscle-weakening autoimmune disease, which "the last quarter they just said had done $1.5 billion in revenue." Argenx wants to push that one molecule to 10 approved uses by 2030, and management "pretty much came out and said, you know, that's the playbook and we're looking to repeat it with Forte's antibody." The company's market value is "above 50 billion" and "trading near its all-time high." In other words: this is a healthy, growing biotech with no cliff of its own choosing to become an acquirer for the first time.

BioCentury's editors put it in the wider frame that makes it a theme rather than a one-off: "the buy side roster has grown." Their examples piled up quickly: "Vertex just made a $10 billion deal… GenMab [paid] $8 billion for Merus last year… Insight [Incyte] buying Vega for more than a billion dollars up front just this month," and Biogen's roughly "$7 billion for Reata" a couple of years back. These are mid-to-large biotechs, "not really a big pharma," now competing head-to-head for the same assets the giants want. As one editor noted, a big drugmaker told them a few months ago that when chasing a particular deal, "they were absolutely aware of one of these" biotech buyers, and it "does change their decision making." The blunt takeaway: "With more buyers in play, there's more competition for deals." More bidders is exactly what pushes takeover prices up and hands sellers the upper hand.

An operator's reality check: the cliff is real, but the cash is picky. The most grounded voice this week came from someone who has sat on both sides of the table. On Life Science Success, "Stella Vnook: Building the Precision Oncology Future at Kaida BioPharma!" (July 31), Stella Vnook, a startup CEO who spent 14 years at Merck before founding cancer-drug developer Kaida BioPharma, so treat this as insider and operator color, laid out the funding picture in plain terms:

"We all hear about there's a massive patent cliff in large pharma. So therefore, there must be a great opportunity for M&A. And that's true. We see a lot of momentum… For us, though, most of that activity is after completed phase one or phase two."

That last line is the whole point. ("Phase one and phase two" are the first human trials, testing safety and early signs a drug works.) Big pharma is happy to buy, Vnook argues, but overwhelmingly to buy drugs that have already been de-risked by early clinical data. Companies still trying to fund their very first human trial are stuck: "The money is out there… However, how the money is distributed and to whom has changed." She points to two shifts drawing dollars away from early-stage US biotech: a rush toward "AI-driven, almost fintech-like approaches to pharma," and a preference for "acquiring assets that have completed their phase one outside of U.S., which we know is much cheaper and faster." Her own company is now weighing running an early trial abroad for the same reason, and has learned to raise "based on milestones and inflection points rather than just" one big lump. She calls 2026 "that transition year."

The host, Don Davis, drew out the risk hiding in that gap: large drugmakers, he said, have to be thinking, "if we don't step in and do something… these companies may not be there whenever we do need them." The cliff creates demand for finished assets, but if the earliest-stage companies get starved today, the pipeline pharma will want to buy in five years may simply not exist.

The reopened financing window is now visible in the data. Last week a fund manager claimed the market for taking biotechs public had swung back open after three shut years. This week a panel of biotech insiders and investors on Biotech Hangout, "Episode 190" (July 24), operator and investor color rather than sell-side research, showed it happening in real time.

The headline was Scribe going public: "probably the first very early stage company to go public since the COVID era," a gene-silencing company whose lead drug (aimed at high cholesterol) only cleared its first regulatory hurdle in Australia "less than two months ago." It priced "at over $100 million" and was upsized. Panelist Brian Skorney was measured about what it signals, not a top, but "certainly a signal of an increasing risk tolerance in the market." For scale, the crew reminded listeners how far this is from the last mania: the biggest biotech IPO ever, back in 2021, was SANA Biotechnology raising "over $600 million" at a "$4.5 billion" valuation before it even had a drug in humans, and SANA "has struggled" ever since. Scribe's raise, at a fraction of that, suggests enthusiasm without the 2021 delirium.

The second data point was a financing structure worth understanding, because it's becoming common. Josh Schimmer flagged that a company called Mentari is merging into a shell company (a "reverse merger," a shortcut to a stock listing that skips the traditional IPO process) alongside a "nearly $300 million" private placement. His tally: "This is actually now the sixth reverse merger in biotech that's been accompanied by a $200 million plus financing. Last year was about three, the year before that one." A backdoor to the public market, supersized with cash, is quietly becoming a real third option for small biotechs.

The debate

The bull case this week is narrower and more mechanical than last week's. It is not "look how much Lilly is spending." It is structural: the number of credible buyers is rising, with Argenx, Vertex, GenMab, Incyte and Biogen all cited as active acquirers below the mega-cap tier, which mathematically tightens competition for every good asset and pushes prices up. Pair that with a reopened financing window that gives sellers a real alternative to selling, and you get a market where targets hold more cards than they have in years.

The bear case again went unvoiced, and that is worth marking rather than celebrating. For the second week running, no guest argued that buyers are overpaying, that the deals will not work, or that regulators might get in the way. Two weeks ago antitrust and drug-pricing risk were the centerpiece of the conversation; this week no one reached for them. To be fair to the tape, no episode this week took on the FTC, antitrust, or the "most-favored-nation" pricing fight head-on, so the one-sidedness partly reflects what got recorded rather than a considered dismissal of the risks. When a hot market stops articulating what could go wrong, the missing bear case is a setup, not reassurance.

The names in play

Treat these as what podcast guests actually discussed this week, not as deal chatter or recommendations.

• Argenx / Forte is the concrete deal of the week. Argenx (roughly $2.2 billion, its first-ever acquisition) is betting Forte's CD122 antibody can become a multi-disease franchise the way its own Vivgart did. Watch whether other "graduated" biotechs follow the same buy-a-second-platform move.
• The widening buyer bench, per BioCentury's editors: Vertex ("just made a $10 billion deal"), GenMab ("$8 billion for Merus last year"), Incyte ("buying Vega for more than a billion dollars up front just this month"), and Biogen ("$7 billion for Reata" a couple of years ago). The point isn't any single name, it's that the acquirer list now runs well below the traditional big-pharma club.
• Arvinas is a read from the seller's side. On BioSpace, "Life after the lead asset: Advancing an early-stage pipeline" (July 30), CEO Randy Thiel (an operator) explained why Arvinas, a pioneer of "protein degrader" drugs, which destroy disease-causing proteins rather than just blocking them, chose to out-license its newly approved breast-cancer drug to Rigel (after a long partnership with Pfizer) and redeploy the cash into its earlier-stage programs. Even companies with an approved drug in hand are handing commercialization to larger players and keeping their capital pointed at discovery, the supply side of the same M&A and partnering wave.

Read-throughs

• XBI and small-cap sentiment: risk appetite is climbing, not peaking. The Biotech Hangout panel's read on the capital markets, a very early IPO getting done, reverse-mergers-plus-cash multiplying, and a de-extinction company (Colossal Biosciences) reportedly chasing a "$20 to $30 billion valuation" round, all point to rising risk tolerance without the full-blown 2021 froth. For anyone watching the small- and mid-cap biotech index (the XBI) as a sentiment gauge, the window is opening, and the panel's own framing was that this is mid-cycle enthusiasm, not a blow-off top.
• Policy backdrop: this week it was tariffs, not the IRA. The pharma-policy episode of the week, Daybreak from The Ken, "Why Indian pharma isn't scared of a 100% tariff (yet)" (July 28), covered President Trump's plan to eventually put a 100% tariff on generic medicines imported into the US, a levy that "doesn't actually take effect for two more years" (August 2028), rising to 200% in 2029. India supplies "nearly 50% of all generic medicines consumed in America" and roughly "$8 to $9 billion" of exports a year, so its pharma index and names like Sun Pharma and Cipla sold off on the news. This is a generics-and-supply-chain story, not the US patent-cliff or Medicare-pricing (IRA) fight, but it's a reminder that a 100% tariff Trump already announced in April on patented drug ingredients is a live cost overhang for branded pharma too. No podcast this week connected that dot to the big-cap cliff names directly.

What changed

Last week the story was about who is spending the most, Lilly's twelfth deal of the year and its roughly $23 billion of upfront M&A, plus a sell-side analyst hanging specific price targets on Merck and AbbVie. This week the story moved one level down the food chain: it's now about who counts as a buyer at all. Argenx crossing into dealmaking for the first time, and the roll-call of mid-cap acquirers behind it, says the demand side is broadening, not just deeper pockets, but more pockets.

The other shift worth marking is that the reopened financing window went from claim to evidence: last week it was a fund manager's assertion; this week it was a live early-stage IPO and a sixth outsized reverse-merger deal. The M&A conversation is loud, while the specific loss-of-exclusivity mechanics that anchor this franchise (Merck's Keytruda, Bristol's Eliquis, J&J's Stelara, AbbVie's post-Humira rebuild) stayed off the podcast tape this week. Worth watching whether that reverses as second-quarter earnings roll in.